Epigenomics AG
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Epigenomics AG
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
/ 
Others were interested in
Frequently asked questions
To buy Epigenomics AG stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Epigenomics AG by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Epigenomics AG is ECX:xetr. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Epigenomics AG has its primary listing on Deutsche Börse (XETRA). You can trade Epigenomics AG with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Epigenomics AG is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Epigenomics AG as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Epigenomics AG.